TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02388152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, double high dose
Study: NCT03343093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restore Rehabilitation Program
Description: Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: usual care, surveys every 3 months
Study: NCT01371422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral Block (PVB)
Description: The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Ultrasonography and local infiltration of saline will only be performed
Study: NCT01790295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Description: Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
Study: NCT01139359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darinaparsin
Description: I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
Study: NCT01199068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017 from 0.25 mg to 0.50 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily
Study: NCT03453047

Intervention type: DIAGNOSTIC_TEST
Intervention: S100β and Neuron specific enolase (NSE)
Description: S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.

Intervention type: DIAGNOSTIC_TEST
Intervention: S100β and Neuron specific enolase (NSE)
Description: S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
Study: NCT02719288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLARIX® CORD 1K graft
Study: NCT02264119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole tablet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lefradafiban double chamber sachet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban double chamber sachet
Study: NCT02139774

Intervention type: BEHAVIORAL
Intervention: Walk with Ease
Description: A six week walking program by the Arthritis Foundation

Intervention type: BEHAVIORAL
Intervention: Walk with Ease
Description: A six week walking program by the Arthritis Foundation

Intervention type: BEHAVIORAL
Intervention: Walk with Ease
Description: A six week walking program by the Arthritis Foundation
Study: NCT03444402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation I)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation I)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation I)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation II)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation II)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation II)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026(Nexium 40mg)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026(Nexium 40mg)
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026(Nexium 40mg)
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT04589299

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin
Description: Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin
Description: Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
Study: NCT02876848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMUM e-health tool
Description: If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~* Contact you over the phone or in person to provide medical advice on how to better take your pills,~* Contact your pharmacist(s) and other doctors about your anti-cancer treatment.
Study: NCT06331104

Intervention type: GENETIC
Intervention: gene expression levels
Description: 12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).

Intervention type: GENETIC
Intervention: gene expression levels
Description: 12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
Study: NCT01632189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
Study: NCT04345380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an Alcon Acrysof SN60WF intraocular lens
Description: Patients suffering from senile cataract getting replaced their human crystalline cataractous lens

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an AMO Tecnis ZCB00 intraocular lens
Description: Patients suffering from senile cataract getting replaced their human crystalline cataractous lens

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an Envista MX60 intraocular lens
Description: Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
Study: NCT04411134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR
Description: Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR
Description: Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)
Study: NCT01198483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Micro- Surgery
Description: Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Small-Surgery
Description: Smallincision cataract surgery combined with 23 gauge vitrectomy
Study: NCT01888250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study: NCT04423562

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03894475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AioCare
Description: AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AioCare
Description: AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometer USB CPFS/D (MGC Diagnostics)
Description: Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometer USB CPFS/D (MGC Diagnostics)
Description: Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
Study: NCT00460746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC125, Darunavir; Ritonavir
Description: TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
Study: NCT01597492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab plus Early Vaccination
Description: Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab plus Late Vaccination
Description: Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
Study: NCT04350879

Intervention type: OTHER
Intervention: Data record
Description: Data record
Study: NCT03518502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Description: Standard therapy for intermediate HCC, but nor for advanced HCC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard therapy for advanced HCC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard therapy for advanced HCC
Study: NCT00702026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multispecies probiotic (Ecologic 801)
Description: once daily, 5 gram \[10e9 cfu/gram\]

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, 5 gram \[10e9 cfu/gram\]
Study: NCT02247297

Intervention type: PROCEDURE
Intervention: Blood collection
Description: Diagnostic blood collection
Study: NCT02265939

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPO-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13
Study: NCT00799799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK cells infusion after immunosuppressive chemotherapy
Study: NCT02518815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Bair Paws Warming System
Description: 20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
Study: NCT01256580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin; Genentech, Inc.)
Description: 1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Description: Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
Study: NCT02312206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01008163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-351/Placebo
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-351/Placebo
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-351
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison of different dosages of drug
Study: NCT03672175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 hard gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 hard gelatin capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matched placebo hard gelatin capsules.
Study: NCT02818998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Study: NCT02444468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowtron ACS800
Description: Flowtron ACS800 and bandage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Bandage only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: Bandage only
Study: NCT04570696

Intervention type: OTHER
Intervention: NON INTERVENTIONAL
Description: NON INTERVENTIONAL
Study: NCT00905034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m\^2 by vein on days 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-l-asparaginase
Description: 2500 International units/m\^2 by vein on days 2 and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth daily days 1-4 and 15-18.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
Study: NCT01938313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative cares
Description: 1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~7. Epidural patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~10. Perioperative High content Oxygen therapy~11. No drain insertion~12. No Levin tube~13. Patients will be discharged at POD#4 if there's no problem.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional perioperative cares
Description: 1. No Patient's preoperative counseling \& education before surgery~2. Bowel preparation~3. No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~5. Conventional Mobilization~6. Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~7. IV PCA~8. Postoperative Nausea Control if needed~9. No Thromboembolism prophylaxis~10. No or Low Content Oxygen therapy~11. Routine drain insertion~12. Levin tube insertion if needed
Study: NCT03040609

Intervention type: BEHAVIORAL
Intervention: Visual-behavioral Scale at day 1
Description: To perform the classification with the scale by caregiver.

Intervention type: BEHAVIORAL
Intervention: Test-retest at the end of 2 weeks
Description: To perform the classification with the scale by orthoptist at the end of 2 weeks

Intervention type: BEHAVIORAL
Intervention: Test-retest at the end of 2 weeks
Description: To perform the classification with the scale by orthoptist at the end of 2 weeks

Intervention type: BEHAVIORAL
Intervention: Test at 6 months
Description: To perform the classification with the scale by orthoptist at the end 6 months.

Intervention type: BEHAVIORAL
Intervention: Test at 6 months
Description: To perform the classification with the scale by orthoptist at the end 6 months.

Intervention type: BEHAVIORAL
Intervention: Test at 6 months
Description: To perform the classification with the scale by orthoptist at the end 6 months.
Study: NCT00632021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Intervention for Low-Literacy in Cardiovascular Disease
Description: Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
Study: NCT02000128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioimpedance monitoring
Description: To assess the body composition using Multi-frequency bioelectrical impedance analysis

Intervention type: OTHER
Group type: OTHER
Intervention: clinical monitoring
Description: clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
Study: NCT02640105

Intervention type: OTHER
Intervention: Neurological clinical examination
Description: Diagnostic and description of cluster headache

Intervention type: OTHER
Intervention: Psychological clinical examination
Description: Scale and questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: Psychopathological and cognitive questionnaires

Intervention type: OTHER
Intervention: Blood sample
Description: Blood sample for DNA collection

Intervention type: OTHER
Intervention: Endothelial function measurement
Description: Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device